Marksans Pharma, 524404, MARKSANS Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

4,801.27
17.44
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

4,127.90
0.47%
2.64

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.39
13.12
10.41

EBITDA CAGR (%)

10 Years
5 Years
3 Years

11.53
20.76
-0.02

PAT CAGR (%)

10 Years
5 Years
3 Years

13.99
28.35
4.12

P:E (Median)

8 Years
5 Years
3 Years

15.33
11.85
11.92

P:BV (Average)

8 Years
5 Years
3 Years

3.01
2.20
2.50

EV:EBITDA (Average)

8 Years
5 Years
3 Years

12.92
7.69
7.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 23 Jun 22 Var% Mar 23 Mar 22 Var% Dec 22 Dec 21 Var% Sep 22 Sep 21 Var%
Net Sales 182.04 159.15 14.38% 153.05 176.28 -13.18% 172.75 165.94 4.10% 170.26 168.85 0.84%
Expenses 155.28 147.55 5.24% 130.34 149.41 -12.76% 148.93 138.12 7.83% 136.49 134.92 1.16%
EBITDA 26.76 11.61 130.49% 22.71 26.87 -15.48% 23.82 27.82 -14.38% 33.77 33.93 -0.47%
EBIDTM 14.70% 7.29% 14.84% 15.24% 13.79% 16.77% 19.84% 20.09%
Other Income 32.62 19.43 67.88% 4.30 7.65 -43.79% 15.71 12.07 30.16% 21.03 8.60 144.53%
Interest 0.26 0.82 -68.29% 0.66 1.28 -48.44% 0.85 0.69 23.19% 1.29 1.20 7.50%
Depreciation 4.72 4.52 4.42% 3.51 4.61 -23.86% 4.18 4.52 -7.52% 4.53 4.30 5.35%
PBT 54.40 25.70 111.67% 22.84 28.63 -20.22% 34.50 34.68 -0.52% 48.98 37.02 32.31%
Tax 10.20 6.50 56.92% 5.04 7.20 -30.00% 8.88 8.62 3.02% 8.75 9.42 -7.11%
PAT 44.19 19.21 130.04% 17.81 21.43 -16.89% 25.62 26.06 -1.69% 40.23 27.60 45.76%
PATM 24.28% 12.07% 11.64% 12.16% 14.83% 15.70% 23.63% 16.34%
EPS 0.98 0.42 133.33% 0.39 0.47 -17.02% 0.57 0.57 0.00% 0.89 0.61 45.90%

Description Jun 23 Jun 22 Var% Mar 23 Mar 22 Var% Dec 22 Dec 21 Var% Sep 22 Sep 21 Var%
Net Sales 500.03 433.77 15.28% 485.98 418.04 16.25% 479.83 362.63 32.32% 452.56 361.20 25.29%
Expenses 398.07 360.91 10.30% 376.43 354.40 6.22% 403.19 304.83 32.27% 372.30 301.10 23.65%
EBITDA 101.97 72.86 39.95% 109.55 63.64 72.14% 76.64 57.80 32.60% 80.27 60.10 33.56%
EBIDTM 20.39% 16.80% 22.54% 15.22% 15.97% 15.94% 17.74% 16.64%
Other Income 10.10 16.50 -38.79% 11.01 15.34 -28.23% 17.65 12.06 46.35% 14.15 8.57 65.11%
Interest 1.58 1.80 -12.22% 2.44 5.03 -51.49% 2.35 0.95 147.37% 2.54 1.50 69.33%
Depreciation 13.66 11.12 22.84% 13.94 21.36 -34.74% 12.74 8.56 48.83% 14.05 7.39 90.12%
PBT 96.83 76.45 26.66% 104.17 52.60 98.04% 79.20 60.35 31.23% 77.83 59.78 30.19%
Tax 26.39 16.26 62.30% 21.46 22.95 -6.49% 16.90 12.08 39.90% 17.71 13.49 31.28%
PAT 70.44 60.18 17.05% 82.71 29.65 178.95% 62.31 48.27 29.09% 60.12 46.29 29.88%
PATM 14.09% 13.87% 17.02% 7.09% 12.98% 13.31% 13.28% 12.81%
EPS 1.52 1.46 4.11% 1.81 0.69 162.32% 1.57 1.20 30.83% 1.52 1.13 34.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 678.10 655.20 658.29 599.55 433.42 424.16 294.66 215.84 358.13 405.59 314.94 Net Sales Growth 1.18% -0.47% 9.80% 38.33% 2.18% 43.95% 36.52% -39.73% -11.70% 28.78% Cost Of Goods Sold 402.51 394.44 377.59 337.91 245.41 236.34 169.35 112.37 178.18 218.16 169.63 Gross Profit 275.59 260.75 280.70 261.63 188.00 187.82 125.31 103.47 179.95 187.44 145.31 GP Margin 40.64% 39.80% 42.64% 43.64% 43.38% 44.28% 42.53% 47.94% 50.25% 46.21% 46.14% Total Expenditure 571.04 563.30 544.57 485.84 361.93 360.83 265.52 202.15 258.76 299.58 236.23 Power & Fuel Cost - 14.24 11.49 10.90 8.95 8.44 7.26 7.21 7.55 7.74 6.46 % Of Sales - 2.17% 1.75% 1.82% 2.06% 1.99% 2.46% 3.34% 2.11% 1.91% 2.05% Employee Cost - 56.09 60.46 54.64 48.51 46.33 45.86 39.77 26.13 23.65 21.39 % Of Sales - 8.56% 9.18% 9.11% 11.19% 10.92% 15.56% 18.43% 7.30% 5.83% 6.79% Manufacturing Exp. - 4.24 5.25 56.39 32.15 12.69 11.52 11.99 13.99 15.42 13.33 % Of Sales - 0.65% 0.80% 9.41% 7.42% 2.99% 3.91% 5.56% 3.91% 3.80% 4.23% General & Admin Exp. - 21.15 16.58 14.79 16.19 22.68 10.95 10.61 9.42 7.50 7.95 % Of Sales - 3.23% 2.52% 2.47% 3.74% 5.35% 3.72% 4.92% 2.63% 1.85% 2.52% Selling & Distn. Exp. - 53.97 59.37 8.56 10.37 34.30 20.58 20.20 23.48 21.52 17.46 % Of Sales - 8.24% 9.02% 1.43% 2.39% 8.09% 6.98% 9.36% 6.56% 5.31% 5.54% Miscellaneous Exp. - 19.15 13.84 2.64 0.34 0.04 0.00 0.00 0.00 5.59 17.46 % Of Sales - 2.92% 2.10% 0.44% 0.08% 0.01% 0% 0% 0% 1.38% 0% EBITDA 107.06 91.90 113.72 113.71 71.49 63.33 29.14 13.69 99.37 106.01 78.71 EBITDA Margin 15.79% 14.03% 17.28% 18.97% 16.49% 14.93% 9.89% 6.34% 27.75% 26.14% 24.99% Other Income 73.66 60.48 42.25 31.16 0.17 7.93 7.43 17.75 13.21 12.82 8.41 Interest 3.06 3.61 3.80 5.34 7.29 6.56 7.67 4.49 6.20 13.11 15.21 Depreciation 16.94 16.74 17.66 15.19 11.64 8.69 12.25 15.00 14.75 9.03 8.66 PBT 160.72 132.03 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 63.26 Tax 32.87 29.17 30.52 25.95 14.82 12.39 4.23 0.40 20.14 29.58 7.70 Tax Rate 20.45% 22.09% 22.69% 20.87% 28.11% 22.12% 25.41% 3.35% 21.98% 30.59% 12.17% PAT 127.85 102.87 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 55.56 PAT before Minority Interest 127.85 102.87 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 55.56 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 18.85% 15.70% 15.80% 16.41% 8.74% 10.28% 4.22% 5.35% 19.96% 16.55% 17.64% PAT Growth 35.58% -1.08% 5.70% 159.58% -13.11% 250.93% 7.62% -83.84% 6.53% 20.79% EPS 2.82 2.27 2.29 2.17 0.84 0.96 0.27 0.25 1.58 1.48 1.23

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 1,918.40 1,852.14 1,490.84 1,376.18 1,134.21 1,000.07 912.69 767.16 893.33 796.69 630.00 Net Sales Growth 21.75% 24.23% 8.33% 21.33% 13.41% 9.57% 18.97% -14.12% 12.13% 26.46% Cost Of Goods Sold 949.29 921.36 716.81 595.05 567.83 498.01 523.13 458.74 509.69 445.44 367.93 Gross Profit 969.11 930.78 774.02 781.13 566.38 502.07 389.57 308.42 383.63 351.25 262.07 GP Margin 50.52% 50.25% 51.92% 56.76% 49.94% 50.20% 42.68% 40.20% 42.94% 44.09% 41.60% Total Expenditure 1,549.99 1,512.82 1,231.96 1,036.58 941.96 867.92 834.31 734.24 760.91 620.86 516.04 Power & Fuel Cost - 24.50 18.59 16.42 14.38 14.34 11.83 13.27 12.58 9.72 7.80 % Of Sales - 1.32% 1.25% 1.19% 1.27% 1.43% 1.30% 1.73% 1.41% 1.22% 1.24% Employee Cost - 239.37 220.30 197.32 168.42 159.07 147.75 149.70 122.42 72.61 66.44 % Of Sales - 12.92% 14.78% 14.34% 14.85% 15.91% 16.19% 19.51% 13.70% 9.11% 10.55% Manufacturing Exp. - 18.73 12.73 127.47 113.32 77.14 59.90 47.34 50.44 37.59 30.11 % Of Sales - 1.01% 0.85% 9.26% 9.99% 7.71% 6.56% 6.17% 5.65% 4.72% 4.78% General & Admin Exp. - 52.58 37.74 50.67 45.52 51.03 42.51 37.52 36.01 15.35 16.13 % Of Sales - 2.84% 2.53% 3.68% 4.01% 5.10% 4.66% 4.89% 4.03% 1.93% 2.56% Selling & Distn. Exp. - 102.53 119.05 33.54 32.15 68.36 49.14 27.66 29.77 34.47 27.63 % Of Sales - 5.54% 7.99% 2.44% 2.83% 6.84% 5.38% 3.61% 3.33% 4.33% 4.39% Miscellaneous Exp. - 153.75 106.73 16.10 0.34 -0.01 0.05 0.00 0.00 5.67 27.63 % Of Sales - 8.30% 7.16% 1.17% 0.03% 0.00% 0.01% 0% 0% 0.71% 0% EBITDA 368.43 339.32 258.88 339.60 192.25 132.15 78.38 32.92 132.42 175.83 113.96 EBITDA Margin 19.21% 18.32% 17.36% 24.68% 16.95% 13.21% 8.59% 4.29% 14.82% 22.07% 18.09% Other Income 52.91 59.31 41.85 6.69 0.33 4.62 8.47 18.85 12.72 12.23 7.28 Interest 8.91 9.13 8.45 7.99 8.75 9.66 10.22 6.78 10.16 16.05 19.13 Depreciation 54.39 51.85 44.78 36.15 26.66 22.80 26.84 30.09 28.13 16.13 15.69 PBT 358.03 337.65 247.51 302.16 157.17 104.31 49.80 14.90 106.85 155.88 86.41 Tax 82.46 72.33 60.70 63.63 36.42 23.87 14.00 3.56 24.11 43.92 12.79 Tax Rate 23.03% 21.42% 24.52% 21.06% 23.17% 22.88% 28.11% 23.89% 22.56% 28.18% 14.80% PAT 275.58 266.31 184.56 235.94 117.02 76.46 32.94 8.83 78.51 109.39 71.90 PAT before Minority Interest 275.25 265.32 186.81 238.54 120.75 80.44 35.80 11.33 82.74 111.96 73.62 Minority Interest -0.33 0.99 -2.25 -2.60 -3.73 -3.98 -2.86 -2.50 -4.23 -2.57 -1.72 PAT Margin 14.37% 14.38% 12.38% 17.14% 10.32% 7.65% 3.61% 1.15% 8.79% 13.73% 11.41% PAT Growth 49.45% 44.29% -21.78% 101.62% 53.05% 132.12% 273.05% -88.75% -28.23% 52.14% EPS 6.08 5.88 4.07 5.21 2.58 1.69 0.73 0.19 1.73 2.41 1.59

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 1,111.32 784.67 599.72 505.63 470.57 428.97 418.88 422.70 358.18 159.92 Share Capital 45.32 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 52.03 Total Reserves 1,066.01 650.64 558.79 464.69 429.64 388.04 377.95 369.27 304.75 107.89 Non-Current Liabilities 26.48 14.41 23.93 24.79 18.39 17.09 17.30 0.31 0.50 21.68 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.82 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 12.66 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 0.00 Current Liabilities 240.91 190.39 137.26 79.73 133.39 111.22 109.59 111.19 168.43 194.83 Trade Payables 111.58 74.45 64.16 56.65 37.23 33.68 20.60 31.41 44.58 40.50 Other Current Liabilities 97.65 78.95 42.70 10.92 7.34 8.79 0.71 0.68 39.88 73.59 Short Term Borrowings 0.00 5.00 0.00 0.00 77.33 66.31 73.23 40.62 43.52 58.06 Short Term Provisions 31.68 31.99 30.40 12.15 11.50 2.45 15.04 38.49 40.45 22.68 Total Liabilities 1,378.71 989.47 760.91 610.15 622.35 557.28 545.77 534.20 527.11 376.43 Net Block 143.94 135.51 129.09 115.18 102.61 87.89 93.92 97.47 90.01 66.82 Gross Block 318.89 301.34 277.25 248.77 224.90 201.83 195.61 184.48 162.47 130.24 Accumulated Depreciation 174.95 165.83 148.16 133.59 122.28 113.94 101.69 87.01 72.45 63.42 Non Current Assets 440.58 375.75 369.32 355.73 339.98 324.78 329.16 330.16 158.45 135.93 Capital Work in Progress 3.90 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 Non Current Investment 265.75 236.07 236.07 236.07 236.07 236.07 234.29 231.44 67.62 67.62 Long Term Loans & Adv. 26.98 4.16 4.16 4.47 1.29 0.82 0.59 1.25 0.83 1.50 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 938.13 613.73 391.60 254.41 282.37 232.51 216.61 204.04 368.66 240.50 Current Investments 0.54 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 130.95 103.67 93.69 74.60 70.36 42.29 29.24 43.74 51.03 55.61 Sundry Debtors 305.49 246.78 168.93 161.87 177.83 168.87 154.80 133.41 124.63 112.38 Cash & Bank 440.26 224.05 105.61 3.35 1.80 0.71 2.56 3.13 167.54 33.37 Other Current Assets 60.88 12.06 1.91 0.82 32.38 20.62 30.01 23.76 25.46 39.14 Short Term Loans & Adv. 53.71 26.73 21.20 13.76 24.91 14.54 29.92 23.76 25.46 39.14 Net Current Assets 697.22 423.34 254.34 174.68 148.98 121.28 107.02 92.85 200.23 45.67 Total Assets 1,378.71 989.48 760.92 610.14 622.35 557.29 545.77 534.20 527.11 376.43

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 1,745.16 1,202.27 886.50 636.01 542.48 470.86 433.43 454.32 379.76 142.18 Share Capital 45.32 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 52.03 Total Reserves 1,699.85 1,068.24 845.56 595.08 501.55 429.93 392.50 400.89 326.33 90.15 Non-Current Liabilities 93.81 57.05 23.70 24.15 17.14 15.64 16.07 -1.91 1.46 22.16 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.82 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 12.74 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 0.00 Current Liabilities 365.36 380.08 298.97 228.75 232.62 234.68 296.06 259.43 286.24 319.12 Trade Payables 230.60 200.08 168.66 110.33 106.07 77.83 161.78 118.98 107.02 83.18 Other Current Liabilities 42.20 96.80 79.69 58.86 20.90 10.08 0.71 0.68 39.88 96.58 Short Term Borrowings 41.59 41.29 18.74 18.84 99.91 117.41 109.71 87.89 82.19 105.54 Short Term Provisions 50.97 41.92 31.88 40.72 5.74 29.36 23.85 51.88 57.15 33.82 Total Liabilities 2,224.24 1,660.10 1,228.03 902.02 802.46 730.73 751.81 720.20 675.56 490.10 Net Block 486.31 428.31 309.36 302.72 269.73 279.38 266.98 269.65 165.90 145.65 Gross Block 828.26 726.26 551.92 565.39 506.26 495.35 456.49 429.47 297.78 261.70 Accumulated Depreciation 341.95 297.96 242.56 262.67 236.54 215.97 189.52 159.82 131.89 116.05 Non Current Assets 524.57 435.04 325.20 308.45 271.02 280.19 267.92 280.06 166.72 147.15 Capital Work in Progress 9.87 2.57 11.68 0.00 0.00 0.00 0.36 0.00 0.00 0.00 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 28.40 4.16 4.16 5.73 1.29 0.82 0.59 10.41 0.83 1.50 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 1,699.67 1,225.07 902.82 593.59 531.44 450.54 483.88 440.15 508.83 342.95 Current Investments 0.54 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 484.74 424.44 404.32 241.84 293.25 218.12 190.09 167.79 130.11 102.59 Sundry Debtors 416.85 394.78 271.95 243.35 176.60 176.91 247.58 217.29 183.45 169.61 Cash & Bank 714.96 349.26 212.18 93.73 33.54 39.88 25.16 35.30 185.27 46.95 Other Current Assets 82.58 24.36 14.11 11.26 28.06 15.63 21.05 19.76 10.01 23.80 Short Term Loans & Adv. 59.12 31.79 0.00 3.40 0.00 0.00 20.96 19.76 10.01 23.80 Net Current Assets 1,334.31 844.98 603.85 364.83 298.82 215.86 187.82 180.71 222.60 23.83 Total Assets 2,224.24 1,660.11 1,228.02 902.04 802.46 730.73 751.80 720.21 675.55 490.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 51.73 55.97 106.92 107.58 19.81 15.63 -13.62 64.76 112.03 54.18 PBT 132.03 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 63.26 Adjustment 10.91 -7.93 -8.82 19.17 11.57 20.00 12.50 8.82 17.75 14.87 Changes in Working Capital -59.60 -38.77 11.62 46.17 -34.91 -16.33 -22.39 -15.35 28.53 -15.89 Cash after chg. in Working capital 83.34 87.80 127.13 118.06 32.67 20.32 2.06 85.09 142.97 62.24 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -31.62 -31.83 -20.21 -10.49 -12.86 -4.68 -15.69 -20.33 -30.94 -8.06 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -194.62 -128.06 8.87 -24.15 -20.20 -7.55 -7.69 -177.34 -29.14 -2.01 Net Fixed Assets -21.45 -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 -2.62 Net Investments -29.78 -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 0.00 Others -143.39 -103.79 37.61 -0.28 2.87 0.09 6.65 8.49 3.09 0.61 Cash from Financing Activity 210.02 70.86 -13.53 -81.87 0.96 -9.98 20.74 -51.83 51.28 -19.21 Net Cash Inflow / Outflow 67.12 -1.23 102.26 1.55 0.56 -1.90 -0.57 -164.41 134.17 32.96 Opening Cash & Equivalents 81.19 82.42 3.35 1.80 0.55 2.45 3.13 167.54 33.37 0.41 Closing Cash & Equivalent 148.31 81.19 105.61 3.35 1.12 0.55 2.56 3.13 167.54 33.37

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 237.41 99.26 178.59 233.33 27.40 50.09 14.06 30.80 154.51 64.84 PBT 337.65 247.51 302.16 157.17 104.31 49.80 14.90 106.85 109.40 71.91 Adjustment 74.24 35.31 56.57 42.04 31.88 43.99 26.58 39.63 24.26 19.57 Changes in Working Capital -111.47 -110.70 -131.61 59.12 -81.79 -36.23 -6.04 -88.14 20.27 -26.01 Cash after chg. in Working capital 300.43 172.12 227.12 258.33 54.40 57.56 35.44 58.34 153.94 65.47 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -63.01 -72.86 -48.53 -25.00 -27.00 -7.46 -21.37 -27.54 -0.89 -0.27 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -259.21 -84.39 -44.85 -59.58 -13.48 -38.81 -20.73 -123.01 -33.19 -4.49 Net Fixed Assets -21.45 -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 -2.62 Net Investments -29.78 -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 0.00 Others -207.98 -60.12 -16.11 -35.71 9.59 -31.17 -6.39 62.82 -0.96 -1.87 Cash from Financing Activity 197.83 79.51 -15.29 -113.55 -20.78 3.38 -3.47 -57.75 16.99 -29.28 Net Cash Inflow / Outflow 176.03 94.38 118.46 60.19 -6.86 14.67 -10.14 -149.96 138.32 31.07 Opening Cash & Equivalents 206.41 112.03 93.73 33.54 39.72 25.05 35.30 185.27 46.95 15.88 Closing Cash & Equivalent 382.44 206.41 212.18 93.73 32.85 39.72 25.16 35.30 185.27 46.95

Financial Ratios

Consolidated /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 24.52 16.90 14.65 12.35 11.50 10.48 10.23 10.02 8.45 3.80 ROA 8.69% 11.88% 14.35% 6.15% 7.40% 2.25% 2.14% 13.47% 14.85% 16.18% ROE 11.41% 16.11% 17.80% 7.77% 9.70% 2.93% 2.79% 18.91% 27.27% 45.75% ROCE 14.27% 19.91% 23.46% 11.39% 11.99% 4.92% 3.44% 22.45% 33.41% 34.89% Fixed Asset Turnover 2.24 2.30 2.30 1.83 1.99 1.48 1.14 2.06 2.77 2.44 Receivable days 144.90 114.03 99.91 143.04 149.17 200.47 243.69 131.50 106.64 118.09 Inventory Days 61.56 54.14 50.83 61.04 48.47 44.31 61.71 48.29 47.98 61.96 Payable days 86.07 66.99 65.25 47.33 37.28 36.94 45.72 53.08 52.33 53.91 Cash Conversion Cycle 120.38 101.18 85.49 156.75 160.37 207.84 259.68 126.70 102.30 126.15 Total Debt/Equity 0.00 0.01 0.00 0.00 0.17 0.16 0.17 0.10 0.14 0.56 Interest Cover 37.54 36.44 24.26 8.23 9.54 3.17 3.66 15.77 8.37 5.16

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 38.51 27.10 21.66 15.54 13.25 11.50 10.59 10.79 8.97 3.34 ROA 13.66% 12.94% 22.40% 14.17% 10.49% 4.83% 1.54% 11.86% 19.21% 16.52% ROE 18.59% 18.72% 31.33% 20.49% 15.88% 7.92% 2.59% 20.45% 45.15% 73.02% ROCE 22.89% 23.82% 39.76% 25.57% 18.51% 10.60% 3.99% 23.16% 44.64% 38.30% Fixed Asset Turnover 2.62 2.42 2.49 2.12 2.00 1.92 1.73 2.46 2.85 2.43 Receivable days 72.63 78.56 67.57 67.57 64.51 84.88 110.59 81.87 80.88 87.17 Inventory Days 81.36 97.65 84.73 86.10 93.32 81.63 85.14 60.86 53.30 52.22 Payable days 85.31 93.88 85.57 45.09 38.48 55.10 65.56 54.58 56.06 48.85 Cash Conversion Cycle 68.67 82.33 66.73 108.58 119.35 111.40 130.17 88.15 78.13 90.54 Total Debt/Equity 0.02 0.04 0.02 0.03 0.18 0.25 0.25 0.19 0.23 1.12 Interest Cover 37.99 30.31 38.84 18.97 11.80 5.87 3.20 11.52 10.72 5.52

Top Investors:

orbimed asia iv mauritius fvci limited

quant mutual fund - quant small cap fund

investor education and protection fund (iepf)

Annual Reports:

News Update:

Marksans Pharma gets USFDA’s final approval for Guaifenesin Extended-Release Tablets
22nd Aug 2023, 14:59 PM

The company expects to launch the product immediately
Read More
Marksans Pharma - Quarterly Results
11th Aug 2023, 18:30 PM

Read More
USFDA completes PADE inspection at Marksans Pharma’s Goa facility
7th Aug 2023, 14:16 PM

The inspection closed with two observations
Read More
Marksans Pharma gets USFDA’s final approval for Acetaminophen and Ibuprofen Tablets
12th Jul 2023, 11:57 AM

The company plans to launch the product immediately
Read More

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: